HighTower Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

HighTower Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-503	Closed	-$2K	–	3464
2022 Q4	$2K	Hold	503	–	–	﹤0.01%	3262
2022 Q3	$2K	Hold	503	–	–	﹤0.01%	3095
2022 Q2	$4K	Sell	503 -30	-6%	-$290	﹤0.01%	3135
2022 Q1	$8K	Hold	533	–	–	﹤0.01%	3228
2021 Q4	$9K	Buy	533 +10	+2%	+$271	﹤0.01%	3158
2021 Q3	$16K	Sell	523 -4	-0.8%	-$158	﹤0.01%	3011
2021 Q2	$29K	Hold	527	–	–	﹤0.01%	2934
2021 Q1	$31K	Buy	527 +1	+0.2%	+$66	﹤0.01%	2872
2020 Q4	$21K	Buy	+526	New	+$19.7K	﹤0.01%	2476

Other funds holding CRBP

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

HighTower Advisors's CRBP Position: Q1 2023 in Review

HighTower Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 503 shares — an estimated $2K sold.

HighTower Advisors first reported a position in CRBP in Q4 2020 and held it in 9 quarters. The position peaked at $31K in Q1 2021. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

HighTower Advisors reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 503 Corbus Pharmaceuticals shares in Q1 2023, an estimated $2K.
HighTower Advisors first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 9 quarters.
HighTower Advisors's Corbus Pharmaceuticals position peaked at $31K in Q1 2021.
30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.